These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35793465)

  • 21. Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.
    Parvathaneni K; Abdeladhim M; Pratt KP; Scott DW
    Transl Res; 2017 Sep; 187():44-52. PubMed ID: 28651073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
    Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
    Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
    Konkle BA
    Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
    Ragni MV
    Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
    Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
    J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.
    Kurth M; Puetz J; Kouides P; Sanders J; Sexauer C; Bernstein J; Gruppo R; Manco-Johnson M; Neufeld EJ; Rodriguez N; Wicklund B; Quon D; Aledort L
    J Thromb Haemost; 2011 Nov; 9(11):2229-34. PubMed ID: 21883884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.
    Ilonczai P; Schlammadinger A; Oláh Z; Rázsó K; Bereczky Z; Boda Z
    Thromb Haemost; 2008 Jul; 100(1):149-50. PubMed ID: 18612550
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of anti-factor VIII antibody levels in patients with haemophilia A receiving immune tolerance induction therapy or bypassing agents.
    Boylan B; Niemeyer GP; Werner B; Miller CH
    Haemophilia; 2021 Jan; 27(1):e40-e50. PubMed ID: 33216433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hemostatic management of hemophilia].
    Tokugawa T
    Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immune coagulation disorders (excluding antiphospholipid syndrome].
    Arai M
    Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations].
    Sutor AH
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):595-9. PubMed ID: 1714865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapies for hemophilia A - the role of the von Willebrand factor chaperone.
    Aguila S; O'Donnell JS
    J Thromb Haemost; 2019 Mar; 17(3):426-428. PubMed ID: 30652400
    [No Abstract]   [Full Text] [Related]  

  • 36. Acquired factor VIII inhibitors.
    Franchini M; Lippi G
    Blood; 2008 Jul; 112(2):250-5. PubMed ID: 18463353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.
    Goudemand J
    Haemophilia; 2007 Dec; 13 Suppl 5():47-51. PubMed ID: 18078397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of von Willebrand factor in immune tolerance induction.
    Ettingshausen CE; Kreuz W
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S27-31. PubMed ID: 15849524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.